Background: Serum biomarkers for diagnosis and risk-stratification of childhood solid
Introduction
Many solid tumors affecting children rely solely on biopsy for diagnosis. Even where diagnostic body fluid markers exist (e.g. urinary catecholamines in neuroblastoma), biopsy is needed to estimate prognosis, including assessment of MYCN-amplification and segmental chromosomal imbalances (1) . The identification of novel body fluid tumor markers that may allow non-invasive diagnosis or risk stratification in solid tumors of childhood would be an important advance. One promising approach is measurement of serum microRNA levels.
MicroRNAs are short, non-protein-coding RNAs that post-transcriptionally regulate gene expression (2) . Importantly, global microRNA profiles have been shown to classify human cancer tissues, including pediatric solid tumors (2, 3) . In pediatric malignant germ cell tumors, for example, the miR-371~373 and miR-302/367 clusters are over-expressed in all cases, regardless of patient age, histologic subtype or anatomic site (2) and thus may represent a universal biomarker of this disease. Packaging of specific microRNAs in membrane-bound exosome particles by tumor cells before release into the bloodstream allows for their detection in the serum (4) . Indeed, we showed that microRNAs from the miR-371~373 and miR-302/367 clusters are detectable at high levels in the serum of patients at the time of malignant GCT diagnosis, and that levels fall with treatment (4-6), findings recently replicated by others (7, 8) . Importantly, these profiles can detect disease at exceptionally low tumor volumes, demonstrating the sensitivity of this approach (6) .
MicroRNAs have many qualities that make them suitable tumor markers for translation into clinical practice, including inherent stability and resistance to degradation, even if samples are left at room temperature or subjected to multiple freeze-thaw cycles (9). We therefore hypothesized that other childhood tumors would be characterized by the release Serum microRNAs in childhood tumors 4 of specific microRNAs into the bloodstream, which would be detectable as an altered serum profile compared with control serum samples.
Here, we report the findings of a proof-of-principle study testing this hypothesis. We addressed three important questions: whether it was feasible to extract RNA from the serum of children in sufficient amounts to undertake global microRNA profiling; whether serum housekeeping microRNAs in children would be similar to those described for adults and thus suitable for normalization purposes, and whether lists of candidate biomarkers could be generated for validation in larger, prospective studies. We undertook global quantitative reverse transcription polymerase chain reaction (qRT-PCR) microRNA profiling in serum samples taken from patients at the time of diagnosis of common childhood cancers (n=33) and compared the results with profiles from age-and gendermatched pediatric control samples (n=20). We describe in detail the detection and analysis pipeline used to make these observations, including highly robust quality control and novel normalization steps, essential for translation of these findings into clinical practice. We identify profiles specific for each of the 11 types of pediatric solid tumor investigated. In particular, we report a panel of serum microRNAs that segregate MYCN-amplified 
Patient demographics and tumor types analyzed
For the main discovery-phase of the project, we initially recruited 34 patients aged 0-16 years (y) at the time of malignant tumor diagnosis (between April 2010 and June 2013), together with a further 20 anonymized samples from a control group of patients without malignant disease. Clinico-pathological details are listed in Table 1 . The tumor group included 18 (53%) male patients and 16 (47%) females with a median age ± standard deviation of 63 ± 59 months. There were no significant differences in age between the male and female patients within the tumor group (p=0.35; two-tailed unpaired t-test). The control group included 11 (55%) male patients and 9 (45%) females with a median age of 49 ± 53 months. There were no significant differences in age between the male and female patients within the control group (p=0.92). There were also no significant differences by age between the tumor and control groups (p=0.74). The 34 tumors were from 11 different (Table 1) .
For the technical confirmation phase of the study, we used 25 samples. These comprised 17 representative tumor and four control serum samples from the discovery-phase test set (Table 1) , plus four independent neuroblastoma serum samples from two MYCN-NB and two NB cases. In total, the confirmatory set comprised four MYCN-NB samples, four NB, three HB, two WT, two RMS, two B-NHL, two HD, two gliomas and four control samples (Table 1) . There was no difference in tumor volume between the MYCN-NB and NB cases. While all four of the MYCN-NB cases were undifferentiated, the grade of the NB cases varied from poorly differentiated to differentiating and ganglio-neuroblastoma (Table   1) .
Data normalization
For details of sample processing, microRNA qRT-PCR profiling and the extensive quality control (QC) steps performed, see Supplementary Materials and Methods. Only a single sample (WT-4) failed initial QC; 53 samples (98%) therefore underwent full qRT-PCR profiling. In initial work, we compared a number of different data normalization methods (12) to define the optimal approach to our global serum microRNA profiling study. We assessed: a) the global mean method, which used the average Ct value of microRNAs expressed in at least one of the 53 samples analyzed, as described (12) Additional analyses were also performed to increase the stringency of our findings further.
Firstly, it was necessary for a microRNA to be detected at least 2 Ct values lower in the test group compared with the 'no template control' (NTC) sample to be included in the subsequent data analysis. Secondly, a co-efficient of variation (CV) was calculated for each over-expressed microRNA, using the formula CV = standard deviation for that microRNA/n, where n was the mean expression value of all microRNAs within that tumor type. This step identified the level of variation in microRNA expression within the specific tumor type and between the control and 'other tumor' group. Thirdly, the Robust Rank Aggregate (RRA) method was employed, as described (15) . For this analysis, samples were processed using the BioConductor package 'RobustRankAggreg' in the statistical software environment R. This algorithm detected microRNAs that were ranked consistently higher than expected under the null hypothesis. This was performed by studying the position of each microRNA in the over-expressed list (ranked by fold-change)
for each specific tumor type, compared with the 'other tumor' and control group. A significance (p-value) score was subsequently assigned for each gene, which calculated how much higher it was positioned in the ranked list than expected by chance, as described (15) . This p-value was adjusted for multiple testing using a Bonferroni correction and was used both for re-ranking the genes and as an indicator of the significance of each gene.
Adjusted scores of p<0.01 were considered significant. Importantly, the RRA method has been used by others in meta-analysis of cancer datasets (16) . Differences in serum microRNA expression levels between experimental groups were assessed using a twotailed t-test (p<0.05 significant).
Serum microRNA qRT-PCR for technical confirmation
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To maximise sensitivity in the technical confirmation study, cDNA was diluted 1:7.5, rather than the standard 1:50 dilution. To ensure robustness for this phase of the study, previously extracted RNA from each serum sample was assessed in technical triplicate.
Each RT product was analyzed by PCR, using the cycling conditions adopted in the discovery-phase full profiling study. The means of the three triplicate values for each microRNA for each sample were calculated. For this targeted work, following QC analysis (Supplementary Materials and Methods), data were normalized using the six top-ranking overlapping housekeeping microRNAs identified in the overlap between the geNorm and NormFinder methods in the full discovery-phase qRT-PCR profiling study. Differences in serum microRNA expression levels between experimental groups were assessed using a two-tailed t-test (p<0.05 significant).
Results

QC and normalization
For full details of the QC steps and the assay pipeline developed, see Supplementary Normalization using the six top-ranking housekeeping microRNAs out of those that were common to the top-ten lists generated using NormFinder and geNorm [namely miR-140-3p
(chromosomal locus 16q22.1), miR-30b-5p (8q24.22), miR-26a-5p (3p22.2), miR-15b-5p (3q25.33), miR-30c-5p (6q13) and miR-191-5p(3p21.31)] (Supplementary Figure S6 ) also performed well in our analysis ( Figure 1B) . Consequently, these six microRNAs were used for normalization purposes for the technical confirmation phase of the study, where only selected findings were being explored. All six of these top-ranking housekeeping microRNAs were transcribed from different genomic loci, adding strength to the suitability of this panel of microRNAs for normalizing all serum expression data, including from adult and pediatric patients. Indeed, five of the six microRNAs were previously reported as being abundant and stably expressed in serum and plasma in adult patients (17) .
Furthermore, two of the six microRNAs (miR-30c-5p and miR-191-5p) overlapped with the four housekeeping microRNAs used for the initial qRT-PCR QC analyses. It should also be noted that the four housekeeping microRNAs used in the initial QC checks (hkgsQC) also performed well for normalization purposes in the full discovery-phase profiling study ( Figure 1B ), indicating their suitability for screening serum samples.
Serum microRNAs in different tumor types
No consistent profile of microRNA over-expression common to all tumor groups was identified when compared with the control group. However, for each of the 11 tumor types studied, we identified microRNAs that were over-expressed compared with both the cohort of other childhood tumors and the control group. The number of such microRNAs ranged from 22 to 49 (mean 34), depending on tumor type (Supplementary Tables S1 and S2 ).
Using the RRA method, the lists were refined to 16 to 26 (mean 21) serum microRNAs in each tumor group (Supplementary Table S1 ). As the MYCN-NB group had the largest coefficient of variance for the delta Ct (miR-23a-3p -miR451a) hemolysis levels (Supplementary Figure S1E) , we only included microRNAs that were ≥2 fold greater than the 'other tumor' group and control group in both of the MYCN-NB samples being interrogated. This reduced the number of microRNAs called as over-expressed in MYCN-NB from 96 to 35 (Supplementary Table S1 ), avoiding identification of serum microRNAs that were released from red blood cells rather than being disease-associated.
Serum microRNAs in childhood tumors 12
The lists of over-expressed serum microRNAs for each tumor group are shown in Supplementary Tables S3 to S13 . Selected findings for the individual tumor groups were used to generate an expression heatmap ( Figure 1C ). MicroRNAs for the heatmap were chosen based on their overall abundance and potential value in differential diagnosis. For two microRNAs (miR-122 and miR-877), the -5p strands were selected rather than the -3p strands identified in the global profiling study, due to the greater abundance of the -5p strands (18) (Supplementary Figure S7) . Ten microRNAs from the heatmap were chosen for subsequent validation in the technical confirmation study (shown in italics in Figure 1C and listed in Supplementary Table S2 Taken together, our data strongly suggest important clinical applications based on serum microRNA quantification. The most promising are described in the following sections.
MYCN-amplified high-risk neuroblastoma (MYCN-NB) vs. non-MYCN-amplified low-risk neuroblastoma (NB).
Treatment schedules for neuroblastoma rely on distinguishing tumors by the presence or absence of INRG high-risk molecular abnormalities, such as MYCN-amplification (1).
Interestingly, our most striking findings were found in the MYCN-NB group. The five Serum microRNAs in childhood tumors 13 over-expressed serum microRNAs (miR-124-3p, miR-9-3p, miR-218-5p, miR-490-5p and miR-1538) that were top-ranking compared with both the 'other tumor' group (including NB samples) and the controls (Supplementary Table S3) analysis of the MYCN-NB versus the NB group in the confirmatory study, there was a significant difference in expression levels for miR-124-3p and miR-9-3p individually (p<0.05) ( Figure 2C ). In addition, in the technical confirmation set, the panel of all five microRNAs successfully distinguished MYCN-NB from NB samples (p=0.031) ( Figure   2C ).
Hepatoblastoma (HB) vs. all neuroblastomas (MYCN-NB/NB).
In children presenting with a liver tumor/enlargement, it may be important to distinguish a primary lesion, such as HB, from involvement by a tumor from elsewhere e.g. for all comparisons) ( Figure 3B ). For the neuroblastomas, there was no association between liver involvement and greater abundance of the HB-associated microRNAs. It was however noted that levels of the liver-specific miR-122-5p (19) were occasionally increased in non-HB samples, for example, in a case of pancreatic RMS presenting with obstructive jaundice (RMS-2) ( Figure 3B ). Accordingly, miR-122-5p needed to be a part of a larger panel to ensure sufficient specificity for HB. In focussed 'differential diagnosis' plots for the HB group versus the combined MYCN-NB/NB group, all three microRNAs were individually significantly elevated in HB (p<0.05 for all comparisons) ( Figure 3C ).
Furthermore, the three microRNA panel also distinguished HB from MYCN-NB/NB (p=0.0001) ( Figure 3C ).
Wilms tumor (WT) vs. all neuroblastomas (MYCN-NB/NB).
Due to their anatomical proximity, it may be difficult both clinically and radiologically to distinguish WT from neuroblastoma; indeed, some neuroblastomas may be intra-renal (20, 21) . Due to the different management and prognosis of these two tumor types, it is important to differentiate them diagnostically (21) . We screened our profiling data from the discovery-phase test set for microRNAs that might be informative in this differential diagnosis setting. We identified miR-129-5p (over-expressed in both the MYCN-NB and NB lists; Supplementary Tables S3 and S4, 
Sarcoma differential diagnosis
Sarcomas may present with bone lesions (ES/OS), soft tissue masses (RMS/ES), or both (ES). Consequently, discriminating these tumors is important, but may be challenging.
Serum microRNAs that were over-expressed for RMS, ES and OS are listed in
Supplementary Tables S7-S9, respectively. Overall levels of representative microRNAs specific for RMS, ES and OS versus the other sarcoma subtypes are illustrated in Figure   1C , (panels 5-7, respectively). In particular, overall analysis ( Figure 5A ) and 'differential diagnosis' plots of the global profiling data (i.e. discovery-phase test set) ( Figure 5B) showed that miR-214-3p, miR-214-5p and miR-92b-3p individually segregated ES from RMS/OS (p<0.05 for all comparisons), as did the three microRNA panel (p=0.0098) ( Figure 5B ). For OS, miR-500a-5p, miR-512-5p and miR-519a-3p showed much higher serum expression than other tumors, including ES (Supplementary Figure S10) .
Discussion
We report a robust, quality controlled pipeline suitable for quantifying serum microRNA levels in pediatric patient cohorts (and potentially adult samples), including the assessment of RNA extraction, degree of sample hemolysis and qRT-PCR efficiency. The described approach minimizes technical alterations and maximizes true biological variation between samples, to allow identification of lists of over-expressed serum microRNAs between study groups, as exemplified here for common solid tumors of childhood. We assessed multiple normalization approaches and identified that for high-throughput global serum microRNA qRT-PCR data, the 'global mean' method (12) was optimal. In addition, we generated a panel of six housekeeping microRNAs that were most stable in pediatric serum samples and therefore suitable for normalizing qRT-PCR data in more targeted lowthroughput studies. Interestingly, the six microRNAs showed substantial overlap with findings from adult samples (17) .
The most striking tumor findings were for MYCN-amplified high-risk neuroblastoma of TH and PHOXB2 representing clinically useful biomarkers of risk (22) . However, potential blood-based mRNA biomarkers can be subject to considerable variation in levels for technical as well as biological reasons (23, 24) . In particular, mRNAs are inherently unstable at room temperature and rapidly degrade in blood samples that are not stored correctly (23, 24) . In contrast, serum microRNAs offer particular advantages as blood-based biomarkers as they are not prone to such technical variations (9). In addition, expression of miR-9 is activated by MYCN protein, which directly binds to the promoter region of this microRNA (27) . In neuroblastoma tissues, high miR-9 levels correlated with MYCN-amplification, tumor grade and metastatic status (27) .
Other tumor-specific serum microRNAs are of biological relevance. For example, miR-122 is highly abundant in liver tissues and is considered liver-specific. Recently, reduced miR-122 expression has been shown in HB compared with normal liver tissue (28) . Here, we found elevated serum levels of miR-122-5p in HB samples compared with other tumors and controls. Down-regulation of miR-122 in HB (compared with normal liver tissue) (28) , but detection at elevated levels in the serum of HB patients is consistent with other observations (11) . Passive leakage of microRNAs from tumor cells into the bloodstream, due to abnormal cellular function, may account for these findings. Alternatively, there may be active and selective microRNA release mechanisms from tumor cells, which may subsequently promote an environment suitable for tumor cell growth and metastasis (11) . It should be noted that miR-122 is a general non-specific marker of liver injury, and is increased in the serum in jaundiced patients, for example (29) . Therefore, a wider panel of serum microRNAs, as identified in this study, is likely to offer increased specificity for HB compared with other tumors and disease states. Of note, one of the additional microRNAs, in the panel that we identified, miR-205, has been shown contribute to hepatocyte differentiation (30) .
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The serum panel for Wilms tumor (WT) included miR-141-5p, which has been reported to be abundant in normal mature renal tissue and down-regulated in WT (31) . The elevated serum miR-141-5p levels at diagnosis in WT patients are likely to be due to the same cellular microRNA release mechanisms suggested for miR-122-5p in HB above. For RMS, serum levels of miR-183-5p were elevated at diagnosis. This is consistent with overexpression of miR-183-5p in RMS tissues, leading to down-regulation of the tumor suppressor transcription factor EGR1 and increased cell migration (32) . For osteosarcoma (OS), seven of the 44 (16%) over-expressed serum microRNAs were from the large microRNA cluster on chromosome 19, at 19q13, termed C19MC, including miR-512-5p
and miR-519a-3p. Serum levels of these microRNAs were very low indeed in other tumor groups and control samples. Interestingly, genomic amplification at 19q13 occurs frequently in OS and may account for these findings (33).
Our detection of a panel of differentially expressed serum microRNAs in central nervous system gliomas (GL) (Supplementary Table S13 ) is likely to reflect disturbance of the blood brain barrier, allowing transfer of microRNAs into the bloodstream. Indeed, similar findings have been reported recently (34). The serum GL panel included miR-155-5p and miR-124-3p. In GL tissues, miR-155 levels were noted to be higher than in normal brain, associated with higher pathological grade and poor clinical outcomes, revealing miR-155 expression as a potential independent prognostic factor and therapeutic target for human glioma (35) . Furthermore, in a study investigating altered microRNA expression during GL malignant transformation, both miR-155-5p (increased) and miR-124-3p (decreased)
showed altered expression between GL stem cells and neural stem cells (36) . Interestingly, apart from MYCN-NB samples, the GL group was the only other in which we could detect miR-124-3p in the serum (Figure 2, panel 1) . MiR-124-3p is under-expressed in pediatric Serum microRNAs in childhood tumors 19 GL (pilocytic astrocytoma) compared with non-neoplastic brain tissue (37) , and again detection in the serum is likely due to active release or passive leak of miR-124-3p from the GL tumor cells across the disrupted blood brain barrier.
As the number of samples assessed for each of the tumor subtypes is small in the present proof-of-principle study, it will be important to confirm our findings in larger, prospective 10=glioma. For tumor abbreviations see Table 1 . Italicized microRNAs were those used for the technical confirmation study. Red=microRNA over-expression;
blue=microRNA under-expression. and control samples or C) each other, in 'differential diagnosis' plots, in the technical confirmation qRT-PCR study. Confirmatory qRT-PCR data were normalized and plotted as described in Figure 2 . Error bars=SEM. For tumor abbreviations see Table   1 .
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